History of Prostate Cancer Linked With Risk for Melanoma

Men with a history of prostate cancer may be at increased risk for melanoma, according to data taken from two large cohort studies.


The FDA granted accelerated approval to pembrolizumab (Keytruda) for treating patients with advanced melanoma who are no longer responding to other drugs.

Pilots and cabin crews were found to have twice the incidence of melanoma and about 40% increased melanoma mortality compared with the general population.

Researchers identified characteristics that may be associated with high-mitotic-rate tumors--being male, elderly, and having a history of solar field damage.

Patients taking a BRAF inhibitor are more susceptible to highly volatile melanocytic lesions that make the detection of new primary melanomas more difficult.

Combined treatment of BRAFV600-mutated melanoma with the MEK inhibitor cobimetinib and the BRAF inhibitor vemurafenib was safe and tolerable, according to the results of a phase Ib study.

Dr. Atkins offers his perspective on the “race” between the top two anti-PD1 drugs (Merck’s MK-3475 and Bristol-Myers Squibb’s nivolumab), and weighs in on where thew new agent pidilizumab fits into the picture.

The presence of regression in melanomas with a Breslow thickness greater than 0.75 mm does not appear to be linked to a higher likelihood of sentinel node involvement, according to the results of a retrospective study.


Subscribe to Melanoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.